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malaria vaccine: analysis of pooled phase II
clinical trial data
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Abstract
Background: RTS,S is the most advanced candidate malaria vaccine but it is only partially protective and the
causes of inter-individual variation in efficacy are poorly understood. Here, we investigated whether peripheral
blood monocyte-to-lymphocyte ratios (ML ratio), previously shown to correlate with clinical malaria risk, could
account for differences in RTS,S efficacy among phase II trial participants in Africa.
Methods: Of 11 geographical sites where RTS,S has been evaluated, pre-vaccination ML ratios were only available
for trial participants in Kilifi, Kenya (N = 421) and Lambarene, Gabon (N = 189). Using time to first clinical malaria
episode as the primary endpoint we evaluated the effect of accounting for ML ratio on RTS,S vaccine efficacy
against clinical malaria by Cox regression modeling.
Results: The unadjusted efficacy of RTS,S in this combined dataset was 47% (95% confidence interval (CI) 26% to
62%, P <0.001). However, RTS,S efficacy decreased with increasing ML ratio, ranging from 67% (95% CI 64% to 70%)
at an ML ratio of 0.1 to 5% (95% CI −3% to 13%) at an ML ratio of 0.6. The statistical interaction between RTS,S
vaccination and ML ratio was still evident after adjustment for covariates associated with clinical malaria risk in
this dataset.
Conclusion: The results suggest that stratification of study participants by ML ratio, easily measured from full
differential blood counts before vaccination, might help identify children who are highly protected and those that
are refractory to protection with the RTS,S vaccine. Identifying causes of low vaccine efficacy among individuals
with high ML ratio could inform strategies to improve overall RTS,S vaccine efficacy.
Trial registration: ClinicalTrials.Gov numbers NCT00380393 and NCT00436007
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Background
Plasmodium falciparum malaria is a major cause of
childhood morbidity and mortality in sub-Saharan Africa
[1,2]. An effective vaccine to complement existing dis-
ease control strategies is urgently needed. RTS,S, cur-
rently in phase III trials in 6- to 12-week-old infants and
5- to 17-month-old children in Africa [3], is the most
advanced P. falciparum malaria vaccine candidate but it
is only partially protective. In previous phase II trials
conducted across 11 geographical sites in Africa, RTS,S
efficacy ranged between 34% and 65% [4-13]. Pooled
analysis of these phase II studies, as well as preliminary
phase III data, found that RTS,S efficacy varied between
individuals according to age at vaccination [3,14] and
the intensity of malaria transmission [15,16].
We have previously shown that a high ratio of monocytes
to lymphocytes (ML ratio) in peripheral blood at cross-
sectional survey correlates with increased susceptibility to
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clinical malaria in older children (median age 4.5 years)
during follow-up [17]. This correlation between ML ra-
tio and clinical malaria risk was evident even after ac-
counting for inter-individual differences in the levels of
antibody correlates of clinical immunity in the study
population [17]. We here investigated whether ML ratio
measured before vaccination could account for inter-
individual variation in RTS,S vaccine efficacy using pub-
lished phase II data.
Methods
Study setting and participants
This study was reported according to the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines (see Additional file 1). The main aim
of this study was to relate pre-vaccination ML ratios to
RTS,S vaccine efficacy from published phase II clinical tri-
als in Africa. We, therefore, sought to use pre-vaccination
ML ratios and efficacy data from all 11 geographical sites
in Africa where RTS,S has been evaluated in phase II clin-
ical trials [16]. Full blood counts, including absolute
lymphocyte count, were available for all sites. However,
most sites did not collect absolute monocyte counts. In-
stead, they used cell counters that returned lymphocyte
count, neutrophil count and a mixed cell count composed
of the sum of monocytes, basophils and eosinophils.
Our analysis was, therefore, restricted to Kilifi, Kenya
[11] and Lambarene, Gabon [12], where absolute per-
ipheral blood lymphocyte and monocyte counts were
collected as distinct cell populations. These clinical
trials are registered at ClinicalTrials.gov, number
NCT00380393 for Kilifi, Kenya and NCT00436007 for
Lambarene, Gabon. At both sites the RTS,S vaccine was
co-administered with the AS01E adjuvant. The respect-
ive local and national ethics committees at both trial
sites granted ethical approval for the studies as detailed
in the primary publications [11,12]. Written informed
consent was obtained from parents or guardians of all
study participants.
The study in Kilifi, Kenya was a phase II double blind,
randomized control trial of RTS,S safety, immunogen-
icity and efficacy when administered in a zero-, one-,
two-month schedule, with a licensed rabies vaccine used
for the control group [11]. This was a multi-center study
of 894 children aged 5 to 17 months at first vaccination,
447 of who were from Kilifi, Kenya and 447 from
Korogwe, Tanzania [11]. Recruitment for screening was
done after public meetings and invitations in the re-
spective communities. Children with any clinical illness,
abnormal blood tests (including full differential blood
count) and severe malnutrition were ineligible for the
study. Vaccinations were performed between March and
August 2007. Clinical malaria episodes (defined as an ax-
illary temperature of ≥37°C accompanied by >2,500
P. falciparum parasites per μl of blood) were monitored
by active surveillance through weekly home visits by
field-workers beginning 2.5 months after the first vaccin-
ation [11]. Only children from Kilifi, Kenya were in-
cluded in the present analysis and the median of the
maximum follow-up duration per child was 14 months
(interquartile range (IQR) 11.8 to 14.8 months) [11].
In Gabon, a randomized, open label trial design was
used to evaluate safety, immunogenicity and efficacy of
RTS,S among infants aged 6 to 10 weeks at first vaccin-
ation. This was also a multi-center study involving a
total of 511 infants of whom 220 were from Lambarene,
Gabon, and the rest from Bagamoyo, Tanzania (N = 210)
and Kintampo, Ghana (N = 81) [12]. Recruitment for
screening was done following community-based infor-
mation programs in Lambarene and Bagamoyo, while an
ongoing demographic surveillance system that includes
monitoring for births was used at Kintampo [18]. Chil-
dren with any clinical or laboratory evidence (including
full differential blood count) of any acute or chronic ill-
ness were ineligible, and all children must have had an
oral polio vaccine and Bacillus Calmette–Guérin (BCG)
vaccine as part of the immunization program for each
country [18]. An aim of that study was to determine the
feasibility of incorporating RTS,S into the Extended Pro-
gram on Immunization (EPI) schedule in infants. Thus,
infants either received the prescribed EPI vaccines alone
(control group) or EPI vaccines in co-administration
with RTS,S [12]. Vaccinations were performed in either
a zero-, one-, two-month schedule or zero-, one-, seven-
month schedule over an eight-month period from April
2007 during a safety and immunogenicity assessment of
RTS,S in infants [18]. For assessment of efficacy, passive
surveillance for clinical malaria episodes whereby par-
ents/guardians had the responsibility to report to a
health facility if their child was ill was done beginning
two weeks after the final vaccination. Clinical malaria
was defined as an axillary temperature of ≥37°C accompan-
ied by a lower parasitemia threshold of >500 P. falciparum
parasites per μl of blood [12]. This was to account for the
younger age and lower levels of naturally acquired
immunity in the studied age group (infants aged 6 to
10 weeks at first vaccination) as has been discussed
in previous clinical malaria case definition studies
[19]. Only children from Lambarene, Gabon were consid-
ered in the present analysis and the median of the
maximum follow-up duration per child was 12 months
(IQR 11.1 to 14.5 months) [12].
The median time interval between measurement of
ML ratio at screening and vaccination was 57 days for
Kenya and 60 days for Gabon, but this was not expected
to confound observed associations since we have previ-
ously shown that ML ratios among healthy children are
stable over time [17].
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Statistical analysis
ML ratio was defined as the ratio between the absolute
peripheral blood monocyte count and lymphocyte count
[17] both acquired using a Coulter counter on blood
sampled at screening before receiving any vaccine. Vac-
cine efficacy was defined as 1 minus the hazard ratio
(HR) following Cox regression modeling with time to
the first or only episode of clinical malaria as the pri-
mary endpoint [11,12]. To estimate RTS,S vaccine effi-
cacy at different levels of ML ratio we tested for a
statistical interaction between pre-vaccination ML ratio
and RTS,S vaccination by Cox regression modeling, with
the trial site included as a fixed effect. We used the mul-
tivariable fractional polynomial method to estimate the
linear and non-linear effects of ML ratio and its inter-
action with RTS,S vaccination, but found no evidence to
support the use of a model accounting for non-linearity
(P = 0.2). We used non-parametric methods to assess the
relationship between pre-vaccination ML ratios and the
following variables: 1) RTS,S-induced peak IgG antibody
levels, measured by enzyme-linked immunosorbent
assay (ELISA) three months after the first vaccination, 2)
RTS,S-induced T cell responses, measured by flow cy-
tometry 12 months after the final vaccination, 3) age at
vaccination, 4) insecticide-treated bed net use, 5) dis-
tance from a health facility, and 6) a weighted local para-
site exposure index [20]. With the exception of bed net
use, where the Mann–Whitney U test was used, all co-
variates were continuous variables and Spearman’s rank
correlation coefficient was used for their univariate
analyses. Of these covariates, only RTS,S-induced anti-
body response data and age at vaccination were avail-
able for both trial sites. All other variables were
available for Kilifi, Kenya only. To account for their ef-
fect on the relationship between RTS,S efficacy and ML
ratio all variables were included in a final Cox regres-
sion model and multivariable fractional polynomials
used to exclude covariates with P-values >0.05 by
backward elimination. Stata™ version 11 (StataCorp LP,
College Station, Texas, USA) was used for all our add-
itional analysis reported here and P-values <0.05 were
considered statistically significant.
Results and discussion
A total of 667 children at both trial sites were randomly
assigned to the RTS,S group or the control group in the
original phase II studies. Of these, pre-vaccination ML
ratios were only available for 610 children (338 in the
RTS,S group and 272 in the control group) to whom the
present analysis is restricted. The median age of this
subgroup of children at the time of vaccination was 8
months (7.5 in the RTS,S group and 10 in the control
group). The median of the maximum follow-up duration
per child was 13.5 months (13.6 in the RTS,S group and
13.4 in the control group). A total of 60 and 83 first or
only clinical malaria episodes were reported in the RTS,
S and control groups, respectively. The unadjusted effi-
cacy of RTS,S against this primary endpoint of time to
first clinical malaria episode in the combined dataset
was 47% (95% CI 26% to 62%, P <0.001).
ML ratio did not directly correlate with clinical malaria
risk among individuals in the RTS,S group (HR = 1.2, 95%
CI 0.58 to 2.66, P = 0.6) or among controls (HR = 0.7, 95%
CI 0.28 to 2.02, P = 0.6). However, there was strong evi-
dence for a statistical interaction between ML ratio and
vaccine efficacy (P = 0.006) suggesting that the protective
effect of vaccination is significantly modified by ML ratio.
RTS,S vaccine efficacy among children with an ML ratio
of 0.1 was 67% (95% CI 64% to 70%) but only 5% (95% CI
−3% to 13%) in those with an ML ratio of 0.6 (Figure 1).
The distribution of ML ratios did not differ between the
RTS,S and control groups thus ruling out any potential
bias from such group differences in the vaccine efficacy es-
timates (Figure 2). A tendency towards an interaction
between ML ratio and RTS,S vaccination was observed
when the cohorts were analyzed separately but did
not reach statistical significance (P = 0.08 for Kenya and
P = 0.05 for Gabon).
As monocytes and lymphocytes play a crucial role in the
induction and maintenance of an immune response, we
determined if ML ratio correlated with antibody or T cell
responses induced by the RTS,S vaccine. For this analysis,
we used previously published antibody and T cell data
[13,21] measured by ELISA and flow cytometry, respect-
ively, using the constituent circumsporozoite (CS) protein
of the RTS,S vaccine as an antigen. ML ratio showed no
association with the peak RTS,S-induced IgG antibody
response to the CS protein (rho = −0.06, P = 0.3; see
Additional file 2), but the interaction between RTS,S and
ML ratio was still evident after adjustment for this variable
(P <0.001). No correlation was observed between ML ratio
and the frequency of CD4+ or CD8+ T cells staining posi-
tive for IFNγ, IL-2 or TNFα on flow cytometry following
restimulation of whole blood with overlapping peptide
pools spanning the full length of CS protein (rho <0.1,
P >0.05 for all). It remains possible that the ML ratio
modifies RTS,S vaccine efficacy independent of the mea-
sured adaptive immune response or that it is an indirect
marker of an as yet unidentified mechanism important for
clinical protection. Though the effect of ML ratio on RTS,
S efficacy does not appear to be through anti-CS protein
IgG antibody quantity, we cannot rule out a role for anti-
body affinity and other functional properties of the in-
duced response. It is noteworthy that the association
between high ML ratio and clinical malaria risk in our pre-
vious longitudinal study of older children with naturally
acquired immunity was independent of antibody corre-
lates of clinical protection in the study population [17].
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We next considered possible confounding by other
covariates. ML ratio was significantly correlated with
age at vaccination (available for both sites; rho = −0.14,
P <0.001), but age was not associated with clinical mal-
aria risk in our dataset (HR = 1.1, 95% CI 0.93 to 1.26,
P = 0.3). We also examined correlations between ML
ratio and covariates associated with clinical malaria risk
in previous studies, namely use of an insecticide-
treated bed net (Mann–Whitney U test z = 1.04, P = 0.3),
distance from a health facility (rho = −0.10, P = 0.04) and a
weighted local parasite exposure index [15,20] (rho = 0.05,
P = 0.3), all available for Kenya only. The statistical inter-
action between RTS,S and pre-vaccination ML ratio was
still evident (P <0.001) in a final model accounting for age,
RTS,S immunogenicity, bed net use, proximity to health
facility and parasite exposure index as covariates.
Together the results suggest that stratification of vaccine
trial participants by ML ratio, easily measured from full
differential blood counts at study enrollment, might help
identify children who are highly protected and those that
are refractory to protection with RTS,S. However, we do
acknowledge several limitations in our analysis.
Pre-vaccination ML ratios were only available at 2 of
11 geographical sites where phase II clinical trials of
RTS,S have been conducted. This clearly limits our abil-
ity to extend our interpretations to other RTS,S study
populations. Further, while we assessed the effect of sev-
eral potential confounders, not all covariates considered
here were available at both trial sites. Nevertheless, it is
encouraging that despite our relatively small sample size,
the effect of ML ratio on RTS,S vaccine efficacy appears
independent of age at vaccination and level of malaria
parasite exposure, two key determinants of inter-
individual variation in RTS,S vaccine efficacy identified
Figure 1 RTS,S vaccine efficacy estimates at different levels of
ML ratio measured before vaccination. In (A), the predicted
efficacy (bold line) and 95% confidence intervals (dashed lines) of
the RTS,S vaccine are shown in relation to the pre-vaccination ML
ratio following bootstrap analysis of a Cox regression model
predicting time to first clinical malaria episode with RTS,S
vaccination, pre-vaccination ML ratio and an interaction term
for both variables as covariates. In (B), the distribution of
pre-vaccination ML ratios for all the 610 children included in
the study is shown.
Figure 2 Distribution of ML ratios among RTS,S vaccinees and
controls. Box-whisker plots are used to compare the distribution of
ML ratios between study participants in the RTS,S and control
groups, respectively. There was no significant difference in the ML
ratio distribution between the two groups (Mann–Whitney U test
z = −1.7, P = 0.1).
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in recent analysis of pooled phase II data and in prelim-
inary analysis of phase III data from all 11 trial sites
[3,14-16]. The much larger ongoing phase III trial of
RTS,S in the same study populations should provide
more conclusive evidence on the relationship between
ML ratio and vaccine efficacy.
Whether interindividual variation in efficacy of other can-
didate malaria vaccines in development correlates with dif-
ferences in pre-vaccination ML ratio remains an open
question. However, recent studies on mouse models have
demonstrated suppression of vaccine immunity by inflam-
matory monocytes and the enhancement of vaccine efficacy
against tumors following monocyte depletion at the time of
vaccination [22]. Further, inflammatory monocytes have
been shown to accumulate and suppress anti-viral T cell re-
sponses during chronic lymphocytic choriomeningitis infec-
tion in mice [23]. It is plausible that RTS,S vaccine efficacy
is specifically inhibited by inflammatory monocytes, thus
confounding induction of an effective adaptive response,
but further studies in both animal models and humans will
be needed to confirm this.
Conclusions
In summary, we find that variation in RTS,S vaccine effi-
cacy between individuals can be attributed to differences
in ML ratio measured before vaccination. Defining the
underlying mechanism(s) for low vaccine efficacy among
individuals with high ML ratio may help inform strat-
egies to improve overall RTS,S vaccine efficacy, with
expected benefits to the childhood population in Africa
who bear the brunt of malarial morbidity and mortality.
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